Zydus to acquire stake in Mylab firm for 106 cr
Zydus Lifesciences announced that it will acquire a 6.5% stake in diagnostic firm Mylab Discovery Solutions for Rs 106 crore. Zydus Animal Health, a subsidiary...
Continue ReadingLupin Digital Health leveraging AI/ML to reduce heart attack risks
What are the digital health offerings the company has at present in the Indian market?LDH, a wholly-owned subsidiary of Lupin, has recently unveiled its digital...
Continue ReadingDr Reddys Laboratories Ltd signs for consumption of renewable energy
Dr. Reddy’s Laboratories Limited (the “Company”) has entered into a Security Subscription and Shareholders’ Agreement for consumption and supply of renewable energy, with TEQ Green...
Continue ReadingBiocon Biologics takes over Viatris’ biosimilar biz in over 70 countries
Biocon Biologics said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countries in emerging markets effective July...
Continue ReadingDr Reddy’s launches nutritional gummies to expand neutraceutical portfolio
Foraying into the child nutrition segment, drug maker Dr. Reddy’s Laboratories launched CeleHealth Kidz Immuno Plus Gummies in the Indian market on other day. The...
Continue ReadingAurobindo arm to commercialise biosimilar to treat Crohn’s disease
Aurobindo Pharma subsidiary CuraTeQ Biologics has entered into an exclusive license agreement with U.S. firm BioFactura Inc to commercialise BFI-751, a proposed biosimilar to recombinant...
Continue ReadingDr Reddy’s Laboratories enters trade generic business in India with new division ‘RGenX’
Pharmaceutical company, Dr Reddy’s Laboratories, announced that it is entering into the trade generics business in India with the launch of its new division, ‘RGenX’....
Continue ReadingGranules India completes US FDA audits at Visakhapatnam and Jeedimedtla facilities
Granules India Limited, a pharmaceutical company, has completed the U.S. Food and Drug Administration’s (US FDA) Pre-Approval Inspection (PAI) and GMP audit for their Unit...
Continue ReadingAurobindo Pharma Subsidiary Met Primary Endpoint In Phase 3 Clinical Trial For Trastuzumab Biosimilar Product
Aurobindo Pharma Limited (along with its subsidiaries together referred to as “Aurobindo”) announced that the breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin),...
Continue Reading